Overall, men in the study with higher Decipher Prostate test scores had worse 10-year outcomes with radiotherapy (RT) alone compared to men with lower Decipher Prostate test scores. The 10-year rate ...
SOUTH SAN FRANCISCO, Calif., September 28, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized ...
The US National Comprehensive Cancer Network (NCCN) classification system, commonly used to determine the prognosis of patients with localized prostate cancer, incorporates data on PSA levels, grade ...
Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial Prostate cancer deemed “intermediate risk” by ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback